NCT04198597

Brief Summary

While the investigators continue to work on better understanding Misophonia, it is also important to identify treatments that can help people who are currently suffering. Further, it is important that the treatments provided are acceptable to the people who receive them. In this study, participants will complete one of two treatments the investigators believe can help manage symptoms of Misophonia: The Unified Protocol or process-based therapy. Both treatments will use evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. The aims of this study are (1) to explore the acceptability and feasibility of these treatments for individuals who experience Misophonia and (2) to examine whether these treatments help reduce symptoms associated with Misophonia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 12, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 13, 2019

Completed
9 months until next milestone

Study Start

First participant enrolled

September 11, 2020

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 21, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 21, 2022

Completed
Last Updated

November 25, 2022

Status Verified

December 1, 2021

Enrollment Period

2.2 years

First QC Date

December 12, 2019

Last Update Submit

November 22, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of patients that are satisfied with treatment as measured by the credibility and expectancy questionnaire (CEQ)

    The CEQ is a 6-item measure that asks patients about their perceptions of treatment.

    up to 20 weeks

  • Number of patients who indicate treatment was acceptable to them (i.e., the treatment approach made sense and was perceived as reasonable)

    This form has two questions that assess how satisfied patients were with treatment and how acceptable treatment was to them. The remaining three items are open ended questions that allow patients to provide narrative feedback about their experience in treatment.

    up to 20 weeks

Secondary Outcomes (5)

  • Change in misophonia symptoms as assessed by the Misophonia Questionnaire

    assessed weekly, up to 24 weeks

  • Change in anxiety as measured by the Overall Anxiety Severity and Impairment Scale

    assessed weekly, up to 24 weeks

  • Change in depression as measured by the Overall Depression Severity and Impairment Scale

    assessed weekly, up to 24 weeks

  • Change in anger as measured by the Clinical Anger Scale

    assessed weekly, up to 24 weeks

  • Number of patients who use the skills taught in treatment as measured by the Skill Use Questionnaire

    assessed weekly, up to 24 weeks

Study Arms (4)

Unified Protocol, 2 week baseline

EXPERIMENTAL

Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.

Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders

Unified Protocol, 4 week baseline

EXPERIMENTAL

Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.

Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders

Process-based treatment, 2 week baseline

EXPERIMENTAL

Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.

Behavioral: Process-based Cognitive Behavioral Therapy

Process-based treatment, 4 week baseline

EXPERIMENTAL

Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.

Behavioral: Process-based Cognitive Behavioral Therapy

Interventions

Please see arm/group descriptions

Unified Protocol, 2 week baselineUnified Protocol, 4 week baseline

Please see arm/group descriptions

Process-based treatment, 2 week baselineProcess-based treatment, 4 week baseline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over age 18
  • Able to read English
  • Meet criteria for interfering symptoms of misophonia
  • Live in North Carolina

You may not qualify if:

  • Under age 18
  • Current mania
  • Current psychotic disorder
  • Current anorexia
  • Presents with a condition that requires immediate prioritization in treatment (e.g., suicide planning or intent)
  • Has received any treatment specifically for misophonia in the past year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27701, United States

Location

MeSH Terms

Conditions

misophonia

Study Officials

  • Zachary Rosenthal, Ph.D.

    Duke University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2019

First Posted

December 13, 2019

Study Start

September 11, 2020

Primary Completion

November 21, 2022

Study Completion

November 21, 2022

Last Updated

November 25, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations